Plus Therapeutics (NASDAQ:PSTV) Receives Buy Rating from D. Boral Capital

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $9.00 target price on the stock. D. Boral Capital’s target price would suggest a potential upside of 492.11% from the company’s previous close.

A number of other research analysts have also commented on the stock. Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th. HC Wainwright cut their price objective on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research report on Friday.

Plus Therapeutics Stock Up 3.4 %

Shares of NASDAQ PSTV opened at $1.52 on Friday. The business has a 50-day moving average price of $1.11 and a 200 day moving average price of $1.24. The stock has a market cap of $8.96 million, a PE ratio of -0.60 and a beta of 0.73. Plus Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.67.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.